( In vivo readout of signal transduction...)Improved Vectors for PathDetect Trans-Reporting Systems

Li Xu Tim Sanchez Mary Buchanan Chao-Feng Zheng
Stratagene

Stratagenes PathDetect in vivo signal transduction pathway reporting systems can be used to assess the in vivo activation of signal transduction pathways. To expand the utility of these systems, Stratagene is replacing the pFA-cJun, pFA-CREB and pFA-Elk1 plasmids with new, improved fusion trans-activator plasmids. The pFA2-cJun, pFA2-CREB and pFA2-Elk1 plasmids feature the cytomegalovirus (CMV) promoter for expression of fusion proteins in a wide variety of cell lines and the neomycin-resistance gene for facilitating selection of stable cell lines.

Stratagene recently introduced the PathDetect in vivo signal transduction pathway trans-reporting systems, which are designed for specific, rapid and convenient assessment of the in vivo activation of signal transduction pathways.¹ Researchers are successfully using these reporting systems for studying the in vivo effects of new genes, growth factors, drug candidates and extracellular stimuli on the activation of c-Jun N-terminal kinase^2,3 (JNK), mitogen-activated protein kinase^4,5 (MAPK), cyclic AMP-dependent protein kinase^6,7 (PKA) and other signaling molecules leading to the activation of these kinases. Each PathDetect reporting system includes (1) a pathway-specific fusion trans-activator plasmid, which is an in-frame fusion of an activation domain and the DNA binding domain of the yeast trans-activator GAL4,^6,8 (2) the pFR-Luc reporter plasmid for expression of the Photinus pyralis (firefly) luciferase gene controlled by a synthetic promoter that contains the yeast GAL4 upstream activating sequences (UAS) (3) a positive control plasmid that is known to activate the trans-activator protein and (4) a negative control plasmid that contains only the DNA
'"/>

Source: